European Gene Cell Therapy

Funding programme: Horizon 2020 (N 965241)

Budget: 3M€

Coordinator: University of Edinburgh

Duration: 5 years (Feb 2021 - Jan 2026)

EuroGCT is here to help make sense of gene and cell therapy - from science in the lab to treatments for patients.

The European Consortium for Communicating Gene and Cell Therapy Information (EuroGCT) brings together 47 partner organisations and institutions across Europe with a goal of providing reliable and accessible information about the use of cells and genetic material to treat disease.

EuroGCT’s two major objectives are:

  • To provide patients, people affected by conditions, healthcare professionals, and citizens with accurate scientific, legal, ethical, and societal information related to cell and gene-based therapies.
  • To provide the research community, regulators, and healthcare authorities with an information source on the practical steps needed for cell and gene therapy development.

The consortium comprises leading cell and gene therapy research labs across Europe working together with product developers, ethicists, lawyers, social scientists, patient representatives, and science communicators. 

ECRIN's role in EuroGCT

ECRIN is contributing to the EuroGCT across the project but notably in the support of outreach to the research community.